B. Riley Financial Announces Private Bond Exchange to Reduce Debt by Approximately $46 Million
LOS ANGELES, May 21, 2025 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("BRF" or the "Company"), a diversified financial services company, today announced it has entered into a privately negotiated exchange agreement (the "Agreement") with an institutional investor, which will reduce the Company's total outstanding debt by approximately $46 million.
Pursuant to the Agreement and subject to the completion of certain closing procedures, the investor has agreed to exchange approximately $139 million in outstanding Senior Notes, consisting of $30 million in March 2026 notes, $75 million in December 2026 notes and $35 million in January 2028 notes, for $93 million in newly issued 8.00% Senior Secured Second Lien Notes due January 1, 2028 (the "Notes"). In addition, the Company is issuing to the investor warrants to purchase an aggregate of approximately 372,000 common shares at an exercise price of $10.00 per share. The warrants are exercisable for a period of seven years from the issuance date.
Bryant Riley, Chairman and Co-Chief Executive Officer of BRF, said: "We've made significant progress addressing our capital structure over the past several months as we've negotiated three bond exchanges to reduce our total outstanding debt by approximately $93 million. The exchange announced today represents our largest to date and eliminates more than $100 million in 2026 maturities, representing a significant reduction in near-term debt and an important step forward for B. Riley. We expect to opportunistically utilize the remaining capacity under our Senior Secured Second Lien facility to further improve our balance sheet."
Moelis & Company LLC acted as financial advisor and Sullivan & Cromwell LLP acted as legal advisor to BRF with respect to the Agreement.
No Offer or Solicitation
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall it constitute an offer to sell, solicitation or sale of securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful.
About B. Riley Financial
B. Riley Financial (BRF) is a diversified financial services company that delivers tailored solutions to meet the strategic, operational, and capital needs of its clients and partners. BRF leverages cross-platform expertise to provide clients with full service, collaborative solutions at every stage of the business life cycle. Through its subsidiaries and affiliated entities, BRF provides end-to-end financial services across investment banking, institutional brokerage, private wealth and investment management, financial consulting, corporate restructuring, operations management, risk and compliance, due diligence, forensic accounting, litigation support, appraisal and valuation, auction, and liquidation services. BRF opportunistically invests to benefit its shareholders, and certain affiliates originate and underwrite senior secured loans for asset-rich companies. BRF refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. For more information, please visit www.brileyfin.com.
Forward-Looking Statements
Statements made in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. You should not place undue reliance on such forward-looking statements, which are based on the information currently available to us and speak only as of today's date. All statements other than statements of historical fact are forward-looking statements and include the completion of the closing procedures related to the exchange. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and the Company assumes no duty to update forward-looking statements, except as required by law. Actual future results, performance or achievements may differ materially from historical results or those anticipated depending on a variety of factors, some of which are beyond the control of the Company, including, but not limited to, the risks described from time to time in the Company's periodic filings with the SEC, including, without limitation, the risks described in the Company's 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" (as applicable). These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. All information is current as of the date this press release is issued, and the Company undertakes no duty to update this information.
ContactsInvestorsir@brileyfin.com
Mike FrankVP Corporate Development & Investor Relationsmfrank@brileyfin.com
Mediapress@brileyfin.com
View original content:https://www.prnewswire.com/news-releases/b-riley-financial-announces-private-bond-exchange-to-reduce-debt-by-approximately-46-million-302461798.html
SOURCE B. Riley Financial
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Prediction: Nvidia Will Soar in the Second Half
Nvidia stock was a sure winner over the past two years before slipping a few months ago. Investors worried that import tariffs would weigh on growth. Since then, though, positive momentum has returned. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) was a surefire winner for investors over the past two calendar years. The artificial intelligence (AI) giant soared more than 800% over that time as it wowed investors with its explosive earnings growth. And as they aimed to get in on the AI growth story, Nvidia seemed like the obvious choice. After all, this tech player sells the world's top-performing AI chips, a critical product for customers building AI platforms. But earlier this year, Nvidia stock slid into the doldrums alongside the rest of the tech market. This happened as investors worried about the impact of U.S. import tariffs on the consumer and corporate earnings. The idea was that this could lead to companies reining in spending, which might include lower spending on AI, potentially bad news for Nvidia. On top of this, U.S. controls on chip exports to China also weighed on Nvidia's growth potential. These concerns resulted in a decline of nearly 30% in Nvidia stock from the start of the year through early April. Since then, though, the stock and the general market have rebounded and even gone on to advance. Nvidia has climbed more than 60% from its low, while the S&P 500 and the Nasdaq have both recorded new record highs. Now, my prediction is that this movement isn't over, and Nvidia will soar in the second half. Let's find out why. First, though, let's take a look at the Nvidia story so far to understand what may lie ahead. Nvidia wasn't always synonymous with AI. In fact, the company's graphics processing units (GPUs) were originally most known for powering video games. But the GPU's ability to handle many tasks simultaneously prompted Nvidia to create the parallel computing platform CUDA and expand the chip's uses into other industries, including AI. This proved to be a key move for the company, as AI has helped revenue skyrocket, as you can see in the chart below. Importantly, Nvidia isn't just growing revenue but also increasing profitability on sales. We can see this in gross margin figures, which have exceeded 70% in recent quarters. The one exception was in the latest quarter, when the gross margin slipped to 60% due to a charge linked to export controls -- U.S. restrictions blocked planned sales, resulting in a billion-dollar charge. Excluding the charge, though, gross margin still topped 70%. Now, let's consider why Nvidia stock could surge in the months ahead. One major point is that the stock today is reasonably priced at 36 times forward earnings estimates, down from more than 50 times just a few months ago. This offers Nvidia stock plenty of room to run, and recognizing this, investors may pile into the shares. Also, general trade-related news could act as a catalyst for stock performance. So far, trade talks and deals suggest that tariff levels may not be as high as originally planned, and any confirmation of this moving forward may boost stocks, particularly growth stocks like Nvidia that thrive in strong economic environments. News from Nvidia itself could boost the stock in the months to come, too. Considering the strong spending plans of Nvidia's customers, from Meta Platforms to Alphabet, and given that the launch of the company's Blackwell platform is rather recent, there's reason to be optimistic about revenue figures in the next quarter. Since Nvidia has committed to an annual rhythm of chip updates, we should also monitor the rollout of the next one -- the Blackwell Ultra -- in the second half. This has just begun and may act as another positive catalyst. Investors will appreciate seeing evidence that Nvidia is able to keep up this pace of annual updates, potentially resulting in share price gains. Finally, the overall AI market is booming, with demand for infrastructure buildout continuing and the next stages of AI, such as the use of AI agents, ready to unfold. This growth environment, with the AI market forecast to reach into the trillions of dollars in a few years, is clearly positive for the leading seller of AI chips. All this means that Nvidia, even if faced with certain hurdles -- such as a halt in chip sales to China -- has many other growth drivers propelling earnings higher right now. And this could continue well into the future. That's why I predict that Nvidia, after a first half of ups and downs, will soar in the second half of the year. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Meta Platforms, and Nvidia. The Motley Fool has a disclosure policy. Prediction: Nvidia Will Soar in the Second Half was originally published by The Motley Fool
Yahoo
4 hours ago
- Yahoo
Sanofi's (NASDAQ:SNY) Riliprubart Granted Orphan Frug Designation in Japan
Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that its Riliprubart has been granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy. Riliprubart is a monoclonal antibody that specifically inhibits activated C1s in the classical complement pathway. The treatment is designed to block a very specific part of the immune system's response. Orphan drug designation is a special status granted by regulatory bodies for medicines that target rare diseases or conditions where there is a high unmet medical need. Dozens of pharmaceutical capsules piled on top of one another to show the scale of the company's drug contributions to the industry. This is a significant achievement for Sanofi (NASDAQ:SNY) because, despite existing treatments, around 30% of patients do not respond adequately, leaving a significant unmet medical need. Sanofi (NASDAQ:SNY) presented 76-week long-term data from a phase 2 clinical trial at the Peripheral Nerve Society meeting in Edinburgh. The results suggest sustained efficacy and safety of Riliprubart in a broad range of CIDP patients. Management noted that two phase 3 studies are underway to further evaluate the treatment. While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
4 hours ago
- Business Insider
Upcoming Stock Splits This Week (July 7 to July 11)
These are the upcoming stock splits for the week of July 7 to July 11, based on TipRanks' Stock Splits Calendar. For those new to the concept, a stock split is a corporate strategy that increases the number of shares in circulation by granting existing shareholders additional shares. While this move doesn't change the company's overall market value, it does lower the share price, making the stock more affordable, and often more appealing, to everyday investors. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. But it's not always about making shares cheaper. Some companies go in the opposite direction with a reverse stock split, combining shares to boost the price per share while reducing the total number. This maneuver, which also leaves the company's market value untouched, is often used to meet exchange requirements and avoid the risk of delisting. Whether the goal is to attract a broader base of investors or simply to stay in the game, these corporate moves can send important signals that savvy traders pay attention to. Let's take a look at the upcoming stock splits for the week. Fly-E Group (FLYE) – Fly-E designs and sells smart electric motorcycles, bikes, and scooters for urban commuters and adventure-seekers alike. On July 2, the company announced a 1-for-5 reverse stock split to boost its share price and remain in compliance with Nasdaq listing standards. The split becomes effective July 7, when shares begin trading on a split-adjusted basis. BioVie (BIVI) – BioVie is a biopharmaceutical innovator working to develop therapies for NASH and other serious fibrotic diseases. On June 26, the company approved a 1-for-10 reverse stock split aimed at raising the share price above Nasdaq's minimum threshold. The split will be reflected in trading starting July 7. Revelation Biosciences (REVB) – With its sights set on breakthrough treatments for chronic kidney disease, Revelation Biosciences is taking proactive steps to stay ahead. The company announced a 1-for-3 reverse stock split to meet Nasdaq's listing standards, following approval at its Special Meeting of Stockholders held on June 23. The split will take effect on July 7. Cyclacel Pharmaceuticals (CYCC) – Cyclacel Pharmaceuticals is a clinical-stage biotech working to create small-molecule cancer drugs that may redefine oncology treatment. On July 2, the company announced a 1-for-15 reverse stock split to keep its shares above Nasdaq's minimum price requirement. The split will be in effect starting July 7. Nuwellis (NUWE) – Nuwellis, a trailblazer in medical-tech fluid management tools for heart and kidney patients, has finalized its 1-for-42 reverse stock split. The split became effective after the close of business on July 3, and trading on a split-adjusted basis will begin at the open on Monday, July 7. La Rosa Holdings (LRHC) – La Rosa is a real estate brokerage and PropTech company serving residential markets across the United States. On July 2, the company announced an 80-for-1 reverse stock split to comply with Nasdaq's minimum bid price. The split will be effective July 7. Banzai International (BNZI) – Banzai delivers essential marketing and sales technology solutions to businesses globally. On July 3, the company announced a 1‑for‑10 reverse stock split, designed to lift its per-share price and comply with Nasdaq's $1 minimum bid requirement following a steep share-price decline. This split will be effective at market open on July 8. Boqii Holding Limited (BQ) – Boqii is China's leading e-commerce platform for pet products. On July 1, the company announced a 1‑for‑160 reverse stock split, consolidating every 160 ordinary shares into one and terminating its ADS facility to simplify its NYSE American listing. The split becomes effective on July 11.
